At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences ...

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

Adjusted profit $1.81 per share vs analyst estimates of $1.79 Company says FDA lenacapavir review still expected by June 19 Biktarvy sales rise 7%, cell therapy sales fall 3% April 24 (Reuters) - ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

The dispute centred around Gilead's triple-drug regimen Biktarvy, which is based on emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir. ViiV claimed the latter compound ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Gilead Sciences, Inc.

FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some ...

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences ...